Details of Drug

Drug General Information (ID: D0048)
Drug Name	Altretamine
Drug Type	Small molecule
Drug Synonymous	Altretamina; Altretaminum; HEXAMETHYLMELAMINE; HMM; HTM; HXM; Hemel; Hexalen; Hexastat; Hexinawas; Altretamine Bellon Brand; Altretamine Chiesi Brand; Altretamine Wassermann Brand; Bellon Brand of Altretamine; Chiesi Brand of Altretamine; MGI Pharma Brand of Altretamine; Rhone Poulenc Rorer Brand of Altretamine; Wassermann Brand of Altretamine; A 8723; ENT 50852; NC 195; Altretamina [INN-Spanish]; Altretaminum [INN-Latin]; Hexalen (TN); Hexalen, Altretamine; KB-913; Rhone-Poulenc Rorer Brand of Altretamine; Altretamine (USP/INN); Altretamine [USAN:INN:BAN]; No-s-triazine; N,N,N',N',N'',N''-hexamethyl-1,3,5-triazine-2,4,6-triamine; N~2~,N~2~,N~4~,N~4~,N~6~,N~6~-Hexamethyl-1,3,5-triazine-2,4,6-triamine; 2,4, 6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylami; 2,4,6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylamino-s-triazine; 2-N,2-N,4-N,4-N,6-N,6-N-hexamethyl-1,3,5-triazine-2,4,6-triamine Click to Show/Hide
Disease Class	2C73: Ovarian cancer
Therapeutic Class	Antineoplastics
Structure
Structure	3D Structure		2D Structure
Formula	C9H18N6
InChI	1S/C9H18N6/c1-13(2)7-10-8(14(3)4)12-9(11-7)15(5)6/h1-6H3
InChIKey	UUVWYPNAQBNQJQ-UHFFFAOYSA-N
Canonical SMILES	CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C
External Link
	Pubchem ID	2123
	CAS Number	645-05-6
	CHEBI ID	24564
	TTD ID	D02LPF

Drug-Drug Interaction Network
Sunburst Graph		Legend Information AM001 Affected gastrointestinal absorption AM004 Affected intra/extra-hepatic metabolism AM006 Pharmacodynamic additive effects AM007 Pharmacodynamic antagonistic effects BM006 Altered intestinal mucosa BM017 CYP450 enzyme inhibition BM022 CYP450 enzyme induction BM042 Additive hypotensive effects BM043 Additive immunosuppressive effects BM044 Additive myelosuppressive effects BM047 Additive thrombogenic effects BM072 Increased risk of nephrotoxicity BM100 Antagonize the effect of vaccine/toxoid BM105 Antagonize the effect of probiotics BM106 Diminish the response to diagnostic skin test antigens BM107 Attenuated pharmacological effects (Unspecific)
Relation Graph

Full list of drugs interacting with Altretamine
Affected gastrointestinal absorption
	Altered intestinal mucosa					Drug Num: 15
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0340		Cinoxacin	C12H10N2O5	2762	Minor		Inter Info	[81]
D0341		Ciprofloxacin	C17H18FN3O3	2764	Minor		Inter Info	[81]
D0438		Delafloxacin	C18H12ClF3N4O4	487101	Minor		Inter Info	[81]
D0712		Gatifloxacin	C19H22FN3O4	5379	Minor		Inter Info	[81]
D0716		Gemifloxacin	C18H20FN5O4	9571107	Minor		Inter Info	[81]
D0919		Levofloxacin	C18H20FN3O4	149096	Minor		Inter Info	[81]
D0943		Lomefloxacin	C17H19F2N3O3	3948	Minor		Inter Info	[81]
D1102		Nalidixic acid	C12H12N2O3	4421	Minor		Inter Info	[81]
D1155		Norfloxacin	C16H18FN3O3	4539	Minor		Inter Info	[81]
D1165		Ofloxacin	C18H20FN3O4	4583	Minor		Inter Info	[81]
D1499		Sparfloxacin	C19H22F2N4O3	60464	Minor		Inter Info	[81]
D1657		Trovafloxacin	C20H15F3N4O3	62959	Minor		Inter Info	[81]
D0573		Enoxacin	C15H17FN4O3	3229	Minor		Inter Info	[81]
D0740		Grepafloxacin	C19H22FN3O3	72474	Minor		Inter Info	[81]
D1092		Moxifloxacin	C21H24FN3O4	152946	Minor		Inter Info	[81]
Affected intra/extra-hepatic metabolism
	CYP450 enzyme inhibition					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0337		Cimetidine	C10H16N6S	2756	Moderate		Inter Info	[50], [38]
	CYP450 enzyme induction					Drug Num: 8
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0071		Amobarbital	C11H18N2O3	2164	Moderate		Inter Info	[36]
D1040		Methylphenobarbital	C13H14N2O3	8271	Moderate		Inter Info	[36]
D1265		Phenobarbital	C12H12N2O3	4763	Moderate		Inter Info	[36]
D1340		Primidone	C12H14N2O2	4909	Moderate		Inter Info	[36]
D0224		Butabarbital	C10H16N2O3	2479	Moderate		Inter Info	[36]
D0225		Butalbital	C11H16N2O3	2481	Moderate		Inter Info	[36]
D1248		Pentobarbital	C11H18N2O3	4737	Moderate		Inter Info	[36]
D1453		Secobarbital	C12H18N2O3	5193	Moderate		Inter Info	[36]
Pharmacodynamic additive effects
	Additive hypotensive effects					Drug Num: 12
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0072		Amoxapine	C17H16ClN3O	2170	Moderate		Inter Info	[37], [38]
D0361		Clomipramine	C19H23ClN2	2801	Moderate		Inter Info	[37], [38]
D0446		Desipramine	C18H22N2	2995	Moderate		Inter Info	[37], [38]
D0525		Doxepin	C19H21NO	667477	Moderate		Inter Info	[37], [38]
D0526		Doxepin (topical)	C19H21NO	667477	Moderate		Inter Info	[37], [38]
D0853		Isocarboxazid	C12H13N3O2	3759	Moderate		Inter Info	[37], [38]
D1158		Nortriptyline	C19H21N	4543	Moderate		Inter Info	[37], [38]
D1263		Phenelzine	C8H12N2	3675	Moderate		Inter Info	[37], [38]
D1620		Tranylcypromine	C9H11N	19493	Moderate		Inter Info	[37], [38]
D0068		Amitriptyline	C20H23N	2160	Moderate		Inter Info	[37], [38]
D0795		Imipramine	C19H24N2	3696	Moderate		Inter Info	[37], [38]
D1361		Protriptyline	C19H21N	4976	Moderate		Inter Info	[37], [38]
	Additive immunosuppressive effects					Drug Num: 39
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0023		Adalimumab	NA	NA	Major		Inter Info	[1], [2], [3], [4], [5], [6]
D0146		Baricitinib	C16H17N7O2S	44205240	Major		Inter Info	[10], [11], [12]
D0304		Certolizumab pegol	NA	NA	Major		Inter Info	[1], [5], [6]
D0661		Fingolimod	C19H33NO2	107970	Major		Inter Info	[15]
D0736		Golimumab	NA	NA	Major		Inter Info	[1], [2], [3], [4], [5], [6]
D0900		Leflunomide	C12H9F3N2O2	3899	Major		Inter Info	[16], [17]
D1211		Ozanimod	C23H24N4O3	52938427	Major		Inter Info	[11], [18]
D1474		Siponimod	C29H35F3N2O3	44599207	Major		Inter Info	[10], [20]
D1556		Teriflunomide	C12H9F3N2O2	54684141	Major		Inter Info	[16], [17]
D1600		Tofacitinib	C16H20N6O	9926791	Major		Inter Info	[27]
D1666		Upadacitinib	C17H19F3N6O	58557659	Major		Inter Info	[28]
D0348		Cladribine	C10H12ClN5O3	20279	Major		Inter Info	[11], [29]
D0614		Etanercept	NA	NA	Major		Inter Info	[1], [2], [3], [4], [5], [6]
D0802		Infliximab	NA	NA	Major		Inter Info	[1], [2], [3], [4], [5], [6]
D1111		Natalizumab	NA	NA	Major		Inter Info	[32]
D0032		Alefacept	NA	NA	Moderate		Inter Info	[21], [33], [34]
D0033		Alemtuzumab	NA	NA	Moderate		Inter Info	[35]
D0136		Azathioprine	C9H7N7O2S	2265	Moderate		Inter Info	[10], [11]
D0246		Canakinumab	NA	NA	Moderate		Inter Info	[44], [45], [46]
D0443		Denosumab	NA	NA	Moderate		Inter Info	[51]
D0499		Dimethyl fumarate	C6H8O4	637568	Moderate		Inter Info	[52]
D0507		Diroximel fumarate	C11H13NO6	73330464	Moderate		Inter Info	[52]
D1085		Monomethyl fumarate	C5H6O4	5369209	Moderate		Inter Info	[52]
D1140		Niraparib	C19H20N4O	24958200	Moderate		Inter Info	[55]
D1162		Ocrelizumab	NA	NA	Moderate		Inter Info	[56]
D1167		Olaparib	C24H23FN4O3	23725625	Moderate		Inter Info	[11], [57]
D1174		Omacetaxine mepesuccinate	C29H39NO9	285033	Moderate		Inter Info	[58]
D1375		Radium Ra 223 dichloride	NA	NA	Moderate		Inter Info	[66]
D1403		Rilonacept	NA	NA	Moderate		Inter Info	[44], [45], [46]
D1422		Roflumilast	C17H14Cl2F2N2O3	449193	Moderate		Inter Info	[11], [67]
D1487		Sodium phosphate, monobasic (p32)	NA	NA	Moderate		Inter Info	[68]
D1509		Strontium chloride Sr-89	Cl2Sr	5388879	Moderate		Inter Info	[10], [11], [69]
D1610		Topotecan	C23H23N3O5	60700	Moderate		Inter Info	[70]
D1671		Ustekinumab	NA	NA	Moderate		Inter Info	[71]
D1720		Zidovudine	C10H13N5O4	35370	Moderate		Inter Info	[10], [11], [72]
D0085		Anakinra	C20H23N5O7S2	146171046	Moderate		Inter Info	[44], [45], [46]
D0313		Chloramphenicol	C11H12Cl2N2O5	5959	Moderate		Inter Info	[10], [11], [73]
D0314		Chloramphenicol (ophthalmic)	C11H12Cl2N2O5	5959	Moderate		Inter Info	[10], [11], [73]
D0553		Efalizumab	NA	NA	Moderate		Inter Info	[74]
	Additive myelosuppressive effects					Drug Num: 5
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0433		Deferiprone	C7H9NO2	2972	Major		Inter Info	[10], [13], [14]
D1443		Samarium (153Sm) lexidronam	Sm	23951	Major		Inter Info	[19]
D0370		Clozapine	C18H19ClN4	135398737	Major		Inter Info	[11], [30], [31]
D0710		Ganciclovir	C9H13N5O4	135398740	Moderate		Inter Info	[10], [11], [53], [54]
D1676		Valganciclovir	C14H22N6O5	135413535	Moderate		Inter Info	[10], [11], [53], [54]
	Additive thrombogenic effects					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1569		Thalidomide	C13H10N2O4	5426	Major		Inter Info	[24], [25], [26]
Pharmacodynamic antagonistic effects
	Antagonize the effect of vaccine/toxoid					Drug Num: 23
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1744		Bacillus calmette-guerin substrain tice live antigen	NA	NA	Major		Inter Info	[7], [8], [9]
D1839		Measles virus vaccine live attenuated	NA	NA	Major		Inter Info	[7], [8], [9]
D1849		Mumps virus strain B level jeryl lynn live antigen	NA	NA	Major		Inter Info	[7], [8], [9]
D1881		Rotavirus vaccine	NA	NA	Major		Inter Info	[7], [8], [9]
D1882		Rubella virus vaccine	NA	NA	Major		Inter Info	[7], [8], [9]
D1890		Smallpox (Vaccinia) Vaccine, Live	NA	NA	Major		Inter Info	[21], [10], [22]
D1897		Talimogene laherparepvec	NA	NA	Major		Inter Info	[23]
D1914		Typhoid vaccine (live)	NA	NA	Major		Inter Info	[7], [8], [9]
D1920		Varicella Zoster Vaccine (Recombinant)	NA	NA	Major		Inter Info	[7], [8], [9]
D1922		Yellow Fever Vaccine	NA	NA	Major		Inter Info	[7], [8], [9]
D0089		Anthrax vaccine	NA	NA	Moderate		Inter Info	[21], [39], [40]
D0366		Clostridium tetani toxoid antigen (formaldehyde inactivated)	NA	NA	Moderate		Inter Info	[21], [39], [40]
D0755		Hepatitis A Vaccine	NA	NA	Moderate		Inter Info	[21], [39], [40]
D0756		Hepatitis B Vaccine (Recombinant)	NA	NA	Moderate		Inter Info	[21], [39], [40]
D0767		Human papillomavirus type 11 L1 capsid protein antigen	NA	NA	Moderate		Inter Info	[21], [39], [40]
D0803		Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)	NA	NA	Moderate		Inter Info	[21], [39], [40]
D0804		Influenza A virus A/Vietnam/1194/2004 (H5N1) antigen (formaldehyde inactivated)	NA	NA	Moderate		Inter Info	[21], [39], [40]
D0999		Meningococcal polysaccharide vaccine group C	NA	NA	Moderate		Inter Info	[21], [39], [40]
D1259		Pfizer-BioNTech Covid-19 Vaccine	NA	NA	Moderate		Inter Info	[59], [21], [10], [60], [61], [62], [39], [63], [64], [65], [40]
D1307		Poliovirus type 1 antigen (formaldehyde inactivated)	NA	NA	Moderate		Inter Info	[21], [39], [40]
D1662		Typhoid vaccine (inactivated)	NA	NA	Moderate		Inter Info	[21], [39], [40]
D1692		Vibrio cholerae CVD 103-HgR strain live antigen	NA	NA	Moderate		Inter Info	[21], [39], [40]
D1838		Lyme disease vaccine (recombinant OspA)	NA	NA	Moderate		Inter Info	[78]
	Antagonize the effect of probiotics					Drug Num: 2
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1749		Bifidobacterium longum infantis	NA	NA	Moderate		Inter Info	[41], [42], [43]
D1827		Lactobacillus acidophilus	NA	NA	Moderate		Inter Info	[41], [42], [43]
	Diminish the response to diagnostic skin test antigens					Drug Num: 4
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1755		Candida albicans	C29H27N2O12P	118855431	Moderate		Inter Info	[47], [48], [49]
D1765		Coccidioides immitis spherule	NA	NA	Moderate		Inter Info	[47], [48], [49]
D1912		Trichophyton mentagrophytes	NA	NA	Moderate		Inter Info	[47], [48], [49]
D1913		Tuberculin purified protein derivative	NA	NA	Moderate		Inter Info	[47], [48], [49]
	Attenuated pharmacological effects (Unspecific)					Drug Num: 3
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0659		Filgrastim	NA	NA	Moderate		Inter Info	[75], [76], [77]
D1235		Pegfilgrastim	C27H46N4O19	70683024	Moderate		Inter Info	[79], [80]
D1446		Sargramostim	NA	NA	Moderate		Inter Info	[75], [76], [77]

References
1	Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
2	Product Information. Enbrel (etanercept). Wyeth-Ayerst Laboratories, Philadelphia, PA.
3	Product Information. Humira (adalimumab). Abbott Pharmaceutical, Abbott Park, IL.
4	Product Information. Remicade (infliximab). Centocor Inc, Malvern, PA.
5	Product Information. Simponi (golimumab). Centocor Inc, Malvern, PA.
6	FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNFa) blockers now include warnings about infection with Legionella and Listeria bacteria. ".
7	Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison's Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998).
8	Product Information. Attenuvax (measles virus vaccine, live, attenuated). Merck &amp Co, Inc, West Point, PA.
9	Product Information. YF-Vax (yellow fever vaccine). sanofi pasteur, Swiftwater, PA.
10	Cerner Multum, Inc. "Australian Product Information.".
11	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
12	Product Information. Olumiant (baricitinib). Lilly, Eli and Company, Indianapolis, IN.
13	Product Information. Ferriprox (deferiprone). ApoPharma USA Inc, Rockville, MD.
14	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports."
15	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
16	Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
17	Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
18	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
19	Product Information. Quadramet (samarium sm 153 lexidronam) Berlex Laboratories, Richmond, CA.
20	Product Information. Mayzent (siponimod). Novartis Pharmaceuticals, East Hanover, NJ.
21	CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
22	Product Information. Dryvax (smallpox vaccine). Wyeth-Ayerst Laboratories, Philadelphia, PA.
23	Product Information. Imlygic (talimogene laherparepvec). Amgen USA, Thousand Oaks, CA.
24	Figg WD, Arlen P, Gulley J, et al. "A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer." Semin Oncol 28(4 Suppl 15) (2001): 62-6. [PMID: 11685731]
25	Fine HA, Wen PY, Maher EA, et al. "Phase II Trial of Thalidomide and Carmustine for Patients With Recurrent High-Grade Gliomas." J Clin Oncol 21 (2003): 2299-304. [PMID: 12805330]
26	Zangari M, Siegel E, Barlogie B, et al "Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy." Blood 100 (2002): 1168-71. [PMID: 12149193]
27	Product Information. Xeljanz (tofacitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
28	Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
29	Product Information. Leustatin (cladribine). Ortho Biotech Inc, Raritan, NJ.
30	Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
31	Canadian Pharmacists Association "e-CPS."
32	Product Information. Tysabri (natalizumab). Elan Pharmaceutical/Athena Neurosciences Inc, South San Francisco, CA.
33	Product Information. Amevive (alefacept). Biogen, Cambridge, MA.
34	Product Information. Lonsurf (tipiracil-trifluridine). Taiho Oncology, Inc., Princeton, NJ.
35	Product Information. Campath (alemtuzumab) Berlex, Richmond, CA.
36	Paolini A, D'Incalci M "Effect of phenobarbital pretreatment on the metabolism and antitumor activity of hexamethylmelamine." Cancer Treat Rep 70 (1986): 513-6. [PMID: 3084083]
37	Bruckner HW, Schleifer SJ "Orthostatic hypotension as a complication of hexamethylmelamine antidepressant interaction." Cancer Treat Rep 67 (1983): 516. [PMID: 6406063]
38	Product Information. Hexalen Capsules (altretamine). US Bioscience, West Conshohoken, PA.
39	Product Information. Imovax Rabies (rabies vaccine). sanofi pasteur, Swiftwater, PA.
40	Department of Health. National Health Service "Immunisation Against Infectious Disease - "The Green Book". Chapter 6: Contraindications and special considerations.".
41	Borriello SP, Hammes WP, Holzapfel W, et.al "Safety of probiotics that contain lactobacilli or bifidobacteria." Clin Infect Dis 36 (2003): 775-80. [PMID: 12627362]
42	Schlegel L, Lemerle S, Geslin P "Lactobacillus species as opportunistic pathogens in immunocompromised patients." Eur J Clin Microbiol Infect Dis 17 (1998): 887-8. [PMID: 10052559]
43	Salminen MK, Tynkkynen S, Rautelin H, et al. "Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland." Clin Infect Dis 35 (2002): 1155-60. [PMID: 12410474]
44	Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
45	Product Information. Ilaris (canakinumab). Novartis Pharmaceuticals, East Hanover, NJ.
46	Product Information. Kineret (anakinra). Amgen, Thousand Oaks, CA.
47	Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative). Connaught Laboratories Ltd, Toronto, ON.
48	Product Information. Candin (candida albicans extract). Nielsen Biosciences Inc, San Diego, CA.
49	Product Information. Spherulin (coccidioidin skin test). ALK Laboratories Inc, Wallingford, CT.
50	Hande K, Combs G, Swingle R, Combs GL, Anthony L "Effect of cimetidine and ranitidine on the metabolism and toxicity of hexamethylmelamine." Cancer Treat Rep 70 (1986): 1443-5. [PMID: 3098418]
51	Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
52	Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
53	Product Information. Cytovene (ganciclovir). Genentech, South San Francisco, CA.
54	Product Information. Valcyte (valganciclovir) Roche Laboratories, Nutley, NJ.
55	Product Information. Zejula (niraparib). Tesaro Inc., Waltham, MA.
56	Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
57	Product Information. Lynparza (olaparib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
58	Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
59	CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence." .
60	Product Information. Biothrax (anthrax vaccine adsorbed). Emergent BioSolutions Inc., Lansing, MI.
61	Product Information. Fluzone Influenza Vaccine (influenza virus vaccine). Connaught, Swiftwater, PA.
62	Product Information. Havrix (hepatitis A vaccine). SmithKline Beecham, Philadelphia, PA.
63	Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated). GlaxoSmithKline, Research Triangle Park, NC.
64	Product Information. Omnihib (haemophilus b conjugate vaccine). SmithKline Beecham, Philadelphia, PA.
65	CDC Centers for Disease Control and Prevention "Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.".
66	Product Information. Xofigo (radium Ra 223 dichloride). Bayer Pharmaceutical Inc, West Haven, CT.
67	Product Information. Daxas (roflumilast). Nycomed Inc, Princeton, NJ.
68	AnazaoHealth Corporation "P32 Sodium Phosphate."
69	Multum Information Services, Inc. Expert Review Panel.
70	Product Information. Hycamtin (topotecan). SmithKline Beecham, Philadelphia, PA.
71	Product Information. Stelara (ustekinumab). Centocor Inc, Malvern, PA.
72	Product Information. Retrovir (zidovudine). Glaxo Wellcome, Research Triangle Park, NC.
73	Sim SM, Back DJ, Breckenridge AM "The effect of various drugs on the glucuronidation of zidovudine (azidothymidine AZT) by human liver microsomes." Br J Clin Pharmacol 32 (1991): 17-21. [PMID: 1909542]
74	Product Information. Raptiva (efalizumab). Genentech, South San Francisco, CA.
75	Product Information. Granix (tbo-filgrastim). Teva Pharmaceuticals USA, North Wales, PA.
76	Product Information. Leukine (sargramostim). Immunex Corporation, Seattle, WA.
77	Product Information. Stemgen (ancestim) Amgen, Thousand Oaks, CA.
78	Shen AK, Mead PS, Beard CB. The Lyme disease vaccine--a public health perspective. Clin Infect Dis. 2011;52 Suppl 3:s247-s252. [PMID: 21217171]
79	Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
80	Product Information. Neulasta (pegfilgrastim). Amgen, Thousand Oaks, CA.
81	Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]

Details of Drug

Details of Drug

Cite MecDDI

About MecDDI

Correspondence